Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Diseases, Mouth Neoplasms, Neoplasms, Tongue Neoplasms

NCT03429036 2026-04-29

Biospecimen Procurement for Head and Neck Disorders

Recruiting

1,000 enrolled

Head & Neck

Head and Neck Neoplasms, Hearing Disorders, Laryngeal Diseases, Pharyngeal Neoplasms

NCT07419464 2026-04-27

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Phase 2 Recruiting

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases

NCT02128906 2026-04-16

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Phase 2 Recruiting

120 enrolled

Head & Neck

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT01647477 2026-03-13

DEREDIA

Phase NA Terminated

90 enrolled

Head & Neck

Laryngeal Diseases

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

20 enrolled

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Clinical Trials

RADIAN

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

FORTIFI-HN01

INTERLINK-1

H&NRAD-2025-01

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Biospecimen Procurement for Head and Neck Disorders

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

DEREDIA

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations